Shuvo Roy, PhD
Shuvo Roy, PhD, is a translational bioengineer focusing on the development of medical devices to address unmet clinical needs through strong collaboration and a multidisciplinary approach.
Dr. Roy is a professor at the University of California, San Francisco in the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department of the UCSF Schools of Pharmacy and Medicine, and is a faculty affiliate of the California Institute for Quantitative Biosciences (QB3). He is the director of the Biodesign Laboratory located on the Mission Bay campus. In addition, he serves as the Technical Director of The Kidney Project and is a founding member of the UCSF Pediatric Device Consortium. Dr. Roy is the Faculty Director of the joint UCSF-UC Berkeley Master of Translational Medicine (MTM) program. He has developed and currently teaches a course focused on medical device development and commercialization issues. He is the author of more than 100 publications and co-author of five book chapters, and holds multiple patents for device developments.
Before joining UCSF in 2008, Dr. Roy co-directed the BioMEMS Laboratory in the Department of Biomedical Engineering at Cleveland Clinic in Cleveland, Ohio, focusing on clinical applications of MEMS. In 1992 he earned a BS degree, magna cum laude, for triple majors in physics, mathematics, and computer science, from Mount Union College in Alliance, Ohio. In 1995, he earned an MS in electrical engineering and applied physics and, in 2001, he earned a PhD in electrical engineering and computer science, both from Case Western Reserve University in Cleveland, Ohio.
He is the recipient of a Top 40 under 40 award by Crain’s Cleveland Business in 1999 and the Clinical Translation Award at the 2nd Annual BioMEMS and Biomedical Nanotechnology World 2001 meeting. In 2003, Dr. Roy was selected as a recipient of the TR100, which features the world’s 100 Top Young Innovators as selected by Technology Review, the Massachusetts Institute of Technology’s Magazine of Innovation. In 2004, he was presented with a NASA Group Achievement Award for his work on harsh environment MEMS. In 2005, Dr. Roy was named as a Who’s Who in Biotechnology by Crain’s Cleveland Business. In 2005 and 2007, he was recognized as a Cleveland Clinic Innovator. In 2009, he was nominated for the Biotechnology Industry Organization's Biotech Humanitarian Award, which is given in recognition of an individual who has used biotechnology to unlock its potential to improve the earth. In 2012, he was presented the Rising Star Award by BayBio Pantheon, and in that same year, he received the Innovation Pathway 2.0 Award from the Food and Drug Administration (FDA). More recently, he was recognized as a Fellow by the American Institute of Medical and Biological Engineering (AIMBE). He is the recipient of the KidneyX Redesign Dialysis Phase 1 Prize, KidneyX Redesign Dialysis Phase 2 Prize, the KidneyX Artificial Kidney Phase 1 Prize, and most recently, the KidneyX Artificial Kidney Phase 2 Prize.